ROUEEN RAFEYAN: Open Payments
NPI 1003891458 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$401,887 in 385 payments from 14 companies in 2025. Trend: 2023 $429,504 · 2024 $369,086 · 2025 $401,887
Speaker / faculty: $313,127Travel & lodging: $32,924Consulting: $29,290Honoraria: $15,525Food & beverage: $11,021
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 82 | $84,097 |
| Neurocrine BioSciences, Inc. | 59 | $78,796 |
| E.R. Squibb & Sons, L.L.C. | 56 | $54,108 |
| Alkermes, Inc. | 56 | $53,148 |
| Teva Pharmaceuticals USA, Inc. | 35 | $52,781 |
| Otsuka America Pharmaceutical, Inc. | 39 | $44,642 |
| Axsome Therapeutics, Inc. | 21 | $16,944 |
| Vanda Pharmaceuticals Inc. | 15 | $9,966 |
| ABBVIE INC. | 7 | $6,524 |
| Janssen Pharmaceuticals, Inc | 6 | $711 |
Products named: CAPLYTA, INGREZZA, COBENFY, REXULTI, LYBALVI, UZEDY, AUSTEDO XR, ARISTADA.
Industry payments across IL — which companies pay providers there.
